Lisinopril And Hydrochlorothiazide

Lisinopril And Hydrochlorothiazide

Lisinopril And Hydrochlorothiazide Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Lisinopril
Anaphylactoid and Possibly Related Reactions:

Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including lisinopril and hydrochlorothiazide) may be subject to a variety of adverse reactions, some of them serious.

Head and Neck Angioedema:

Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including lisinopril. This may occur at any time during treatment. ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients. Lisinopril and hydrochlorothiazide should be promptly discontinued and the appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. Very rarely, fatalities have been reported due to angioedema associated with laryngeal edema or tongue edema. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (See ADVERSE REACTIONS).

Intestinal Angioedema:

Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.

Patients with a history of angioedema unrelated to ACE-inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also INDICATIONS AND USAGE and CONTRAINDICATIONS).

Anaphylactoid reactions during desensitization:

Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.

Anaphylactoid reactions during membrane exposure:

Thiazide-containing combination products are not recommended in patients with severe renal dysfunction. Sudden and potentially life-threatening anaphylactoid reactions have been reported in some patients dialyzed with high-flux membranes (eg, AN69®*) and treated concomitantly with an ACE inhibitor. In such patients, dialysis must be stopped immediately, and aggressive therapy for anaphylactoid reactions must be initiated. Symptoms have not been relieved by antihistamines in these situations. In these patients, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.

Hypotension and Related Effects:

Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of lisinopril use in salt/volume-depleted persons, such as those treated vigorously with diuretics or patients on dialysis. (See PRECAUTIONS , Drug Interactions and ADVERSE REACTIONS .)

Syncope has been reported in 0.8 percent of patients receiving lisinopril and hydrochlorothiazide. In patients with hypertension receiving lisinopril alone, the incidence of syncope was 0.1 percent. The overall incidence of syncope may be reduced by proper titration of the individual components. (See PRECAUTIONS, Drug Interactions,  ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION .)

In patients with severe congestive heart failure, with or without associated renal insufficiency, excessive hypotension has been observed and may be associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death. Because of the potential fall in blood pressure in these patients, therapy should be started under very close medical supervision. Such patients should be followed closely for the first two weeks of treatment and whenever the dose of lisinopril and/or diuretic is increased. Similar considerations apply to patients with ischemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If hypotension occurs, the patient should be placed in supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses which usually can be given without difficulty once the blood pressure has increased after volume expansion.

Leukopenia/Neutropenia/Agranulocytosis:

Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of lisinopril are insufficient to show that lisinopril does not cause agranulocytosis at similar rates. Marketing experience has revealed rare cases of leukopenia/neutropenia and bone marrow depression in which a causal relationship to lisinopril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

Hepatic Failure:

Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.

Fetal Toxicity

Pregnancy Category D 

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue lisinopril and hydrochlorothiazide as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue lisinopril and hydrochlorothiazide, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to lisinopril and hydrochlorothiazide for hypotension, oliguria, and hyperkalemia (see PRECAUTIONS, Pediatric Use).

No teratogenic effects of lisinopril were seen in studies of pregnant rats, mice, and rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in rats), and 0.6 times (in rabbits) the maximum recommended human dose.

Lisinopril and Hydrochlorothiazide

Teratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of lisinopril (56 times the maximum recommended human dose) in combination with 10 mg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose. Maternal or fetotoxic effects were not seen in mice with the combination. In rats decreased maternal weight gain and decreased fetal weight occurred down to 3/10 mg/kg/day (the lowest dose tested). Associated with the decreased fetal weight was a delay in fetal ossification. The decreased fetal weight and delay in fetal ossification were not seen in saline-supplemented animals given 90/10 mg/kg/day.

When used in pregnancy, during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, discontinue lisinopril and hydrochlorothiazide as soon as possible (See Lisinopril, FETAL TOXICITY).

Hydrochlorothiazide

Acute Myopia and Secondary Angle-Closure Glaucoma 

Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

Teratogenic Effects

Reproduction studies in the rabbit, the mouse and the rat at doses up to 100 mg/kg/day, (50 times the human dose) showed no evidence of external abnormalities of the fetus due to hydrochlorothiazide. Hydrochlorothiazide given in a two-litter study in rats at doses of 4 to 5.6 mg/kg/day (approximately 1 to 2 times the usual daily human dose) did not impair fertility or produce birth abnormalities in the offspring. Thiazides cross the placental barrier and appear in cord blood.

Nonteratogenic Effects

These may include fetal or neonatal jaundice, thrombocytopenia and possibly other adverse reactions have occurred in the adult.

Hydrochlorothiazide

Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug Interactions, Lisinopril and Hydrochlorothiazide).

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).

In using lisinopril and hydrochlorothiazide tablets USP, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS).

In considering use of lisinopril and hydrochlorothiazide tablets USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients. (See WARNINGS, Lisinopril).

History

There is currently no drug history available for this drug.

Other Information

Lisinopril and hydrochlorothiazide tablet USP combines an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide.

Lisinopril, a synthetic peptide derivative, is an oral long-acting angiotensin converting enzyme inhibitor. It is chemically described as (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate. Its empirical formula is C21H31N3O5•2H2O and its structural formula is:

Lisinopril USP

Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.53. It is soluble in water, sparingly soluble in methanol, and practically insoluble in ethanol.

Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8ClN3O4S2 and its structural formula is:

HCTZ USP

Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.

Lisinopril and hydrochlorothiazide tablets USP are available for oral use in three tablet combinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide tablets USP, 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide; lisinopril and hydrochlorothiazide tablets USP, 20 mg/12.5 mg, containing 20 mg lisinopril and 12.5 mg hydrochlorothiazide; and lisinopril and hydrochlorothiazide tablets USP, 20 mg/25 mg, containing 20 mg lisinopril and 25 mg hydrochlorothiazide.

Inactive ingredients are dibasic calcium phosphate, magnesium stearate, mannitol, pregelatinized starch and starch (corn). Lisinopril and hydrochlorothiazide tablets USP, 10 mg/12.5 mg also contains FD&C Blue No. 2 Aluminum Lake. Lisinopril and hydrochlorothiazide tablets USP, 20 mg/12.5 mg also contains yellow iron oxide and lisinopril and hydrochlorothiazide tablets USP, 20 mg/25 mg also contain red iron oxide.

Lisinopril And Hydrochlorothiazide Manufacturers


  • Proficient Rx Lp
    Lisinopril And Hydrochlorothiazide Tablet [Proficient Rx Lp]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Direct Rx
    Lisinopril And Hydrochlorothiazide Tablet [Direct Rx]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Actavis Elizabeth, Llc
    Lisinopril And Hydrochlorothiazide (Lisinopril And Hydrochlorothiazide) Tablet [Actavis Elizabeth, Llc]
  • Physicians Total Care, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Physicians Total Care, Inc.]
  • Udl Laboratories, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Udl Laboratories, Inc.]
  • State Of Florida Doh Central Pharmacy
    Lisinopril And Hydrochlorothiazide Tablet [State Of Florida Doh Central Pharmacy]
  • State Of Florida Doh Central Pharmacy
    Lisinopril And Hydrochlorothiazide Tablet [State Of Florida Doh Central Pharmacy]
  • Lake Erie Medical Dba Quality Care Products Llc
    Lisinopril And Hydrochlorothiazide Tablet [Lake Erie Medical Dba Quality Care Products Llc]
  • Pd-rx Pharmaceuticals, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Pd-rx Pharmaceuticals, Inc.]
  • Rebel Distributors Corp
    Lisinopril And Hydrochlorothiazide Tablet [Rebel Distributors Corp]
  • Preferred Pharmaceuticals, Inc
    Lisinopril And Hydrochlorothiazide (Lisinopril And Hydrochlorothiazide) Tablet [Preferred Pharmaceuticals, Inc]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide (Lisinopril And Hydrochlorothiazide) Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Dispensing Solutions, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Dispensing Solutions, Inc.]
  • International Labs, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [International Labs, Inc.]
  • Preferred Pharmaceuticals, Inc
    Lisinopril And Hydrochlorothiazide Tablet [Preferred Pharmaceuticals, Inc]
  • Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
    Lisinopril And Hydrochlorothiazide Tablet [Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc]
  • Stat Rx Usa Llc
    Lisinopril And Hydrochlorothiazide Tablet [Stat Rx Usa Llc]
  • Lake Erie Medical Dba Quality Care Products Llc
    Lisinopril And Hydrochlorothiazide Tablet [Lake Erie Medical Dba Quality Care Products Llc]
  • Bryant Ranch Prepack
    Lisinopril And Hydrochlorothiazide Tablet [Bryant Ranch Prepack]
  • Watson Laboratories, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Watson Laboratories, Inc.]
  • Ncs Healthcare Of Ky, Inc Dba Vangard Labs
    Lisinopril And Hydrochlorothiazide Tablet [Ncs Healthcare Of Ky, Inc Dba Vangard Labs]
  • Aphena Pharma Solutions – Tennessee, Llc
    Lisinopril And Hydrochlorothiazide Tablet [Aphena Pharma Solutions – Tennessee, Llc]
  • St Marys Medical Park Pharmacy
    Lisinopril And Hydrochlorothiazide Tablet [St Marys Medical Park Pharmacy]
  • Pd-rx Pharmaceuticals, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Pd-rx Pharmaceuticals, Inc.]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Medvantx, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Medvantx, Inc.]
  • Pd-rx Pharmaceuticals, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Pd-rx Pharmaceuticals, Inc.]
  • International Labs, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [International Labs, Inc.]
  • Avkare, Inc.
    Lisinopril And Hydrochlorothiazide (Lisinopril And Hydrochlorothiazide) Tablet [Avkare, Inc.]
  • Clinical Solutions Wholesale
    Lisinopril And Hydrochlorothiazide Tablet [Clinical Solutions Wholesale]
  • Pd-rx Pharmaceuticals, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Pd-rx Pharmaceuticals, Inc.]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Unit Dose Services
    Lisinopril And Hydrochlorothiazide Tablet [Unit Dose Services]
  • Unit Dose Services
    Lisinopril And Hydrochlorothiazide Tablet [Unit Dose Services]
  • Unit Dose Services
    Lisinopril And Hydrochlorothiazide Tablet [Unit Dose Services]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Ranbaxy Pharmaceuticals Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Ranbaxy Pharmaceuticals Inc.]
  • Aurobindo Pharma Limited
    Lisinopril And Hydrochlorothiazide Tablet [Aurobindo Pharma Limited]
  • Lupin Pharmaceuticals, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Lupin Pharmaceuticals, Inc.]
  • Aidarex Pharmaceuticals Llc
    Lisinopril And Hydrochlorothiazide Tablet [Aidarex Pharmaceuticals Llc]
  • Ivax Pharmaceuticals, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Ivax Pharmaceuticals, Inc.]
  • International Labs, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [International Labs, Inc.]
  • International Labs, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [International Labs, Inc.]
  • Apotex Corp.
    Lisinopril And Hydrochlorothiazide Tablet [Apotex Corp.]
  • Remedyrepack Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Remedyrepack Inc. ]
  • Proficient Rx Lp
    Lisinopril And Hydrochlorothiazide Tablet [Proficient Rx Lp]
  • Aphena Pharma Solutions – Tennessee, Llc
    Lisinopril And Hydrochlorothiazide (Lisinopril And Hydrochlorothiazide) Tablet [Aphena Pharma Solutions – Tennessee, Llc]
  • American Health Packaging
    Lisinopril And Hydrochlorothiazide Tablet [American Health Packaging]
  • Bryant Ranch Prepack
    Lisinopril And Hydrochlorothiazide Tablet [Bryant Ranch Prepack]
  • Bryant Ranch Prepack
    Lisinopril And Hydrochlorothiazide Tablet [Bryant Ranch Prepack]
  • Golden State Medical Supply, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Golden State Medical Supply, Inc.]
  • Northwind Pharmaceuticals, Llc
    Lisinopril And Hydrochlorothiazide Tablet [Northwind Pharmaceuticals, Llc]
  • Mylan Pharmaceuticals Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Mylan Pharmaceuticals Inc.]
  • Eon Labs, Inc.
    Lisinopril And Hydrochlorothiazide Tablet [Eon Labs, Inc.]
  • Northwind Pharmaceuticals, Llc
    Lisinopril And Hydrochlorothiazide Tablet [Northwind Pharmaceuticals, Llc]
  • Direct Rx
    Lisinopril And Hydrochlorothiazide Tablet [Direct Rx]
  • Directrx
    Lisinopril And Hydrochlorothiazide Tablet [Directrx]

Login To Your Free Account